QRS duration measured by 12-lead ECG in RA pts treated with TOFA (table 1) . However, an increase in PQ interval duration was observed (p=0,04). There were significantly decrease of mean HR (p<0,003), increase of QRS duration (p<0,03), QTc (p<0.03), night QTc (p<0,02) in 24 h ECG ambulatory recording. HR, PQ, QTc duration were changed independently of beta-blockers therapy. The number of pts with QTc≥440 ms increased from 11% to 21% (p>0.05). A change in QTc duration correlated negatively with dynamics of DAS 28, SDAI (r=-0,4, p<0,05), DM (r=0,5, p<0,02),4, p<0,04). There were also significantly increase number of ventricular premature beats (p<0,03). Background: Methotrexate (MTX) is used as an anchor drug for the treatment of rheumatoid arthritis (RA). Patients with RA have a modestly increased risk of developing lymphoproliferative disorders (LPD). Furthermore, although sometimes spontaneous regression occurs after withdrawal of MTX, LPD developed during the treatment with MTX is broadly defined as MTX-associated LPD (MTX-LPD). Objectives: To characterize the risk factors concerning MTX-LPD and to consider optimal treatment after occurrence of LPD in patients with RA. Methods: We retrospectively evaluated 51 RA patients with LPD from 2006 to 2015 in our institution. MTX-LPD patients were divided into two groups; regressive LPD after MTX cessation (N=27) and persistent LPD though MTX was tapered (N=24), and the clinical characteristics, pathology and treatment outcomes were compared. EBV infection and IL-6 receptor (IL-6R) expression were analyzed by in situ hybridization and immunohistochemistry. Results: There was no significant difference in disease duration, stage, disease activity of RA, the positive rate of Epstein-Barr virus-encoded small RNAs, EBERs (42.7 vs 50.0%) and treatment with TNF-inhibitors (40.7 vs 45.8%) between regressive LPD and persistent LPD. Age of LPD onset (59.1 vs 68.3), CRP (2 vs 5 mg/dl) and the weekly MTX dose (10.9 vs 8.4 mg/w) significantly differed between the groups. Of note, IL-6R was highly expressed in both group (75.0 vs 66.7%). Among regressive LPD, 3 patients developed DLBCL later. persistent LPD showed poorer prognosis and worse mortality than regressive LPD. An older age and anemia were poor prognostic factors. Of 51 patients, 41% achieved sustained low disease activity (LDA) with other DMARDs except MTX. Nine of 10 patients refractory to DMARDs were controlled by tocilizumab (TCZ) and kept LDA. Conclusions: Taken together, it seems unreasonable to be lump the persistentgroup into the same category as MTX-LPD. The high expression rate of IL-6R and the high responsiveness to TCZ suggest that IL-6/IL-6R is likely to play a role in the development of LPD in patients with RA. Objectives: To describe a new assessment tool for patient risk management and report the difference between structured versus expert guided assessment following standard of care in a construct-validation cohort.
THU0150 OPTIMIZING COMORBIDITY RISK MANAGEMENT IN RA BY TRANSLATING A NURSE-LED INTERVIEW INTO AN EASILY INTERPRETABLE TRAFFIC LIGHT SYSTEM
Background: Due to its inflammatory nature, rheumatoid arthritis (RA) is associated with a variety of comorbidities and individual risk factors [1] . The benefit of a nurse-led programme on RA comorbidity management has been reported recently [2] . Objectives: To describe a new assessment tool for patient risk management and report the difference between structured versus expert guided assessment following standard of care in a construct-validation cohort.
Methods:
The ongoing cluster randomized multicentre study ERIKO is longitudinally assessing individual risk profiles of patients with RA in Germany. The aim of this study is to test the benefit of applying a nurse-led scoring algorithm for individual risk profiles followed by a structured patient consultation (active arm) as compared to local standard of care. The ERIKO-Score was calculated by rating validated assessment tools and treatment guidelines and translating their outcome into a three-level ordinal score defined by the categories low, intermediate or high risk, including nominal weights for risk management (e.g. condition is being treated with goals achieved or not). Scores were interpreted numerically by rating categories with 0, 1 and 2 points, respectively. We included cardiovascular (CV) risk (ESC-guideline), infection risk (RABBIT risk calculator), vaccination status (guideline), fracture risk (FRAX), tooth status (PSI), depression-(PHQ-9) and health-related quality of life (hrQoL, RAID). The same risk categorization was prompted in all centres at the screening visit without providing the rating tools. This analysis compares SOC ratings from the screening visit (month zero) with the baseline ERIKO-scores at month three in the active arm. No statistical hypothesis testing was performed in this analysis.
Results: This analysis included 283 patients from 31 centres specialized in rheumatology care randomized to the active study arm. 82.3% were female with a mean age of 57.8 years (sd 12.1) and a mean DAS28 of 2.6 (sd 1.1). The mean total ERIKO-Score was slightly higher at baseline as compared to applying the scoring algorithm on SOC ratings at the screening visit (5.33 +-1.95 vs. 4.32 +-2.61, respectively, table 1). The discrepancy was mainly driven by CV risk, vaccination status, tooth status and depression risk, that were more often rated worse by applying the ERIKO score than by SOC, while infection-and fracture risk were more frequently rated lower by the ERIKO-Score (table 2) . The strongest discrepancy between SOC ratings and ERIKO-Score ( =2 points) were observed for tooth status (N=54), CV risk (N=25) and vaccination status (N=25) (table 2) . SOC ratings were strongly based on expert opinion with the most frequently cited tools being vaccination guidelines (38.9%), bone mineral density measurement (BMD) (39.6%) and RABBIT-infection risk-score (23.1%).
Conclusions:
A nurse-led comorbidity risk assessment in rheumatology practices seems feasible. Applying the ERIKO-Score based on validated tools led to a higher risk grading than the predominantly expert-opinion based SOC. Construct validation of the ERIKO-Score is ongoing. A total of 29 patients were negative for ACPA compared to 44 patients that were positive for ACPA. Osteopenia in lumbar spine was found in 82.2% of patients 65.8% hip and 75.3% in femoral neck. Logistic regression was performed without finding statistically significant association between osteopenia and inflammatory activity (DAS 28), vitamin D levels and positive rheumatoid factor, adjusted for variables that can modify BMD. ACPA Positive (any titer) were associated with the presence of lumbar spine osteopenia (OR 7.19, 95% CI 1.77-29.17) (p=0.006), hip (OR 15.17, 95% CI 3.96-58.18) (p=0.001) and femoral neck (OR 3.76; 95% CI 1.20-11.82) (p=0.023). In addition, a simple variance analysis (ANOVA) was performed to compare T scores and ACPA levels divided into three categories: ≤25U/mL, 25-300U/mL and>300U/mL. ACPA group ≤25U/mL differed in mean T score values in lumbar spine, hip and femoral neck. No differences were found between ACPA positive patients with low and high levels for T score values. Conclusions: ACPA positivity in RA is associated with an increased risk of osteopenia in lumbar spine, hip and femoral neck independently of other variables that may modify bone mineral density. These data suggest that ACPA may play a role in bone remodeling References: Objectives: to characterise patients who are being screened correctly (i.e., in accordance with recommendations).
Methods: Study design:
This was an open long-term (3 years) extension of the COMEDRA 6 month randomized controlled trial in which patients with definite, stable RA were visiting a nurse for comorbidity assessment and screening counselling.
[3] For this analysis, only the final visit data were used crosssectionally. Assessment of comorbidity screening: A score was developed to quantify comorbidity screening procedures in accordance with guidelines: [4] this score gives 50 points to CV risk screening, 20 points to cancer screening, 20 points to pneumococcus and influenza vaccination and 10 points to osteoporosis screening. The score ranges 0-100 and 0 indicates optimal screening. Factors associated with optimal screening: demographic and disease characteristics were compared between patients considered well-screened (lowest tertile for screening score) versus other patients. Statistical analysis: Variables with p<0.20 in univariate analysis were entered into the multivariate analysis using a backward stepwise logistic regression. Results: 769 patients were assessed: mean (±SD) age 62 (±11) years, mean disease duration 17 (±10) years; 614 (80%) were women and 535 (70%) were receiving a biologic. Disease was well-controlled (mean DAS28 2.8±1.3). The mean comorbidity screening score was 24.3 (±17.8) (range, 0-100). The 316 patients (41% of all patients) in the lowest tertile for this score (i.e., with a score ≤15) were less often smokers: odds ratio [95% confidence interval] 0.45 [0.28 -0.72], were more often treated for hyperlipidemia (2.58 [1.85 -3.61]), and were more often treated with a biologic (1.97 [1.4 -2.76]). Conclusions: Comorbidity screening is suboptimal in RA. Patients who were better screened were more frequently already followed-up for hyperlipidemia and were more frequently receiving biologics but more less frequently smokers. Thus it seems getting optimal screening may reflect both patient characteristics but also physician attention to comorbidity in certain situations. Empowering patients to be responsible for the comorbidity screening reminders should be explored. abstract. http://acrabstracts.org/abstract/screening-for-and-managementof-comorbidities-after-a-nurse-led-program-results-of-a-3-year-longitudinalstudy-in-776-established-ra-patients/.
